Last 12 months
Inside the activity.
1 purchase rows · 5 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 2 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2019 Filed Mar 1, 2019 22:01 UTC |
APPIO THOMASPres&Co-Head Bausch&Lomb/Int'l
|
GrantCommon Stock, No Par Value | 21,310 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-009234 · form4.xml · nonDerivative · entry 1 APPIO THOMAS · CIK 0001683323 · Pres&Co-Head Bausch&Lomb/Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,950 F1 · shares: Represents the award of restricted share units ("RSUs") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value ("Common Shares"), of Bausch Health Companies Inc. ("Bausch Health"). Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 21:10 UTC |
Gordon Joseph FPres&Co-Head Bausch&Lomb/Int'l
|
Tax withholdingCommon Shares, No Par Value | 2,169 | $21.25 | $46,091.25 |
DisclosureSEC source: 0001127602-19-001765 · form4.xml · nonDerivative · entry 1 Gordon Joseph F · CIK 0001749876 · Pres&Co-Head Bausch&Lomb/Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,225 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 21:11 UTC |
McKenna Mark C.President, Salix
|
Tax withholdingCommon Shares, No Par Value | 1,190 | $21.25 | $25,287.50 |
DisclosureSEC source: 0001127602-19-001767 · form4.xml · nonDerivative · entry 1 McKenna Mark C. · CIK 0001749623 · President, Salix 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,941 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 21:09 UTC |
Eldessouky SamSVP, CHIEF ACCOUNTING OFFICER
|
Tax withholdingCommon Stock, No Par Value | 1,696 | $21.25 | $36,040.00 |
DisclosureSEC source: 0001127602-19-001763 · form4.xml · nonDerivative · entry 1 Eldessouky Sam · CIK 0001558676 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,421 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 21:04 UTC |
APPIO THOMASPres&Co-Head Bausch&Lomb/Int'l
|
Tax withholdingCommon Stock, No Par Value | 1,722 | $21.25 | $36,592.50 |
DisclosureSEC source: 0001127602-19-001761 · form4.xml · nonDerivative · entry 1 APPIO THOMAS · CIK 0001683323 · Pres&Co-Head Bausch&Lomb/Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,640 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 21:02 UTC |
ACKERMANN CHRISTINAEVP AND GENERAL COUNSEL
|
Tax withholdingCommon Stock, No Par Value | 3,446 | $21.25 | $73,227.50 |
DisclosureSEC source: 0001127602-19-001759 · form4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,010 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 21:22 UTC |
Humphries William D.President, Ortho-Dermatologics
|
Tax withholdingCommon Stock, No Par Value | 13,311 | $18.47 | $245,854.17 |
DisclosureSEC source: 0001127602-19-001498 · form4.xml · nonDerivative · entry 1 Humphries William D. · CIK 0001674278 · President, Ortho-Dermatologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,797 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 21:34 UTC |
WECHSLER AMY BDirector
|
GrantCommon Stock, No Par Value | 1,716 | $18.47 | $31,694.52 |
DisclosureSEC source: 0001127602-19-000723 · form4.xml · nonDerivative · entry 1 WECHSLER AMY B · CIK 0001677300 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,165 F1 · shares: Reflects Restricted Share Units ("RSUs"), each representing a contingent right to receive one common share, no par value, of Bausch Health Companies Inc. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 21:31 UTC |
ROBERTSON RUSSEL CDirector
|
GrantCommon Stock, No Par Value | 2,210 | $18.47 | $40,818.70 |
DisclosureSEC source: 0001127602-19-000712 · form4.xml · nonDerivative · entry 1 ROBERTSON RUSSEL C · CIK 0001677301 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,377 F1 · shares: Reflects Restricted Share Units ("RSUs"), each representing a contingent right to receive one common share, no par value, of Bausch Health Companies Inc. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 21:27 UTC |
Paulson JohnDirector
|
GrantCommon Stock, No Par Value | 1,488 | $18.47 | $27,483.36 |
DisclosureSEC source: 0001127602-19-000700 · form4.xml · nonDerivative · entry 1 Paulson John · CIK 0001394923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,699 F1 · shares: Reflects Restricted Share Units ("RSUs"), each representing a contingent right to receive one common share, no par value, of Bausch Health Companies Inc. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 21:25 UTC |
DE SCHUTTER RICHARD UDirector
|
GrantCommon Stock, No Par Value | 1,691 | $18.47 | $31,232.77 |
DisclosureSEC source: 0001127602-19-000691 · form4.xml · nonDerivative · entry 1 DE SCHUTTER RICHARD U · CIK 0001083205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,635 F1 · shares: Reflects Restricted Share Units ("RSUs"), each representing a contingent right to receive one common share, no par value, of Bausch Health Companies Inc. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 21:22 UTC |
APPIO THOMASPres&Co-Head Bausch&Lomb/Int'l
|
GrantCommon Stock, No Par Value | 25,440 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-036571 · form4.xml · nonDerivative · entry 2 APPIO THOMAS · CIK 0001683323 · Pres&Co-Head Bausch&Lomb/Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,362 F2 · shares: Represents matching Restricted Share Units ("MRSUs") granted to the Reporting Person in connection with the open market purchase of Common Shares of the Issuer reported above (the "Purchased Shares"), pursuant to the Issuer's Matching Share Program. One-third of the MRSUs will vest on each of the first, second, and third anniversaries following the date of grant ("MRSU Grant Date"), subject to the Reporting Person's continued service (except in limited circumstances). Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 21:22 UTC |
APPIO THOMASPres&Co-Head Bausch&Lomb/Int'l
|
PurchaseCommon Stock, No Par Value | 25,440 | $22.96 | $584,018.45 |
DisclosureSEC source: 0001127602-18-036571 · form4.xml · nonDerivative · entry 1 APPIO THOMAS · CIK 0001683323 · Pres&Co-Head Bausch&Lomb/Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,922 F1 · shares: The price in Column 4 is a weighted average price. The prices actually paid in this transaction are within the range of $22.94 to $22.96 per share. Upon request by the Commission staff, the Issuer or the reporting person will provide full information regarding the number of Common Shares purchased by the reporting person at each separate price within the range set forth in this footnote. Read SEC document |
| October 29, 2018 Filed Nov 1, 2018 01:16 UTC |
VON ESCHENBACH ANDREW C.Director
|
GrantCommon Shares, No Par Value | 5,832 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-031509 · form4.xml · nonDerivative · entry 1 VON ESCHENBACH ANDREW C. · CIK 0001536529 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,832 F1 · shares: Represents Restricted Share Units ("RSUs"), each representing a contingent right to receive one Common Share, no par value, of Bausch Health Companies Inc., which will vest immediately before the 2019 Annual Meeting of Shareholders. Read SEC document |
| October 16, 2018 Filed Oct 17, 2018 20:15 UTC |
ACKERMANN CHRISTINAEVP AND GENERAL COUNSEL
|
SaleCommon Stock, No Par Value | 4,542 | $25.50 | $115,821.00 |
DisclosureSEC source: 0001127602-18-030504 · form4.xml · nonDerivative · entry 2 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,456 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 20:15 UTC |
ACKERMANN CHRISTINAEVP AND GENERAL COUNSEL
|
SaleCommon Stock, No Par Value | 15,404 | $24.83 | $382,481.32 |
DisclosureSEC source: 0001127602-18-030504 · form4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,998 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 28, 2018 Filed Oct 2, 2018 20:38 UTC |
WECHSLER AMY BDirector
|
GrantCommon Stock, No Par Value | 1,217 | $25.67 | $31,240.39 |
DisclosureSEC source: 0001127602-18-029071 · form4.xml · nonDerivative · entry 1 WECHSLER AMY B · CIK 0001677300 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,449 F1 · shares: Represents Restricted Share Units ("RSUs") representing a contingent right to receive one common share, no par value, of Bausch Health Companies Inc. Read SEC document |
| September 28, 2018 Filed Oct 2, 2018 20:37 UTC |
ROBERTSON RUSSEL CDirector
|
GrantCommon Stock, No Par Value | 1,460 | $25.67 | $37,478.20 |
DisclosureSEC source: 0001127602-18-029069 · form4.xml · nonDerivative · entry 1 ROBERTSON RUSSEL C · CIK 0001677301 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,167 F1 · shares: Represents Restricted Share Units ("RSUs") representing a contingent right to receive one common share, no par value, of Bausch Health Companies Inc. Read SEC document |
| September 28, 2018 Filed Oct 2, 2018 20:35 UTC |
Paulson JohnDirector
|
GrantCommon Stock, No Par Value | 1,071 | $25.67 | $27,492.57 |
DisclosureSEC source: 0001127602-18-029064 · form4.xml · nonDerivative · entry 1 Paulson John · CIK 0001394923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,211 F1 · shares: Represents Restricted Share Units ("RSUs") representing a contingent right to receive one common share, no par value, of Bausch Health Companies Inc. Read SEC document |
| September 28, 2018 Filed Oct 2, 2018 20:35 UTC |
DE SCHUTTER RICHARD UDirector
|
GrantCommon Stock, No Par Value | 1,217 | $25.67 | $31,240.39 |
DisclosureSEC source: 0001127602-18-029059 · form4.xml · nonDerivative · entry 1 DE SCHUTTER RICHARD U · CIK 0001083205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,944 F1 · shares: Represents Restricted Share Units ("RSUs") representing a contingent right to receive one common share, no par value, of Bausch Health Companies Inc. Read SEC document |
| September 14, 2018 Filed Sep 17, 2018 18:58 UTC |
Herendeen PaulEVP and CFO
|
GrantCommon Stock, No Par Value | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-027736 · form4.xml · nonDerivative · entry 2 Herendeen Paul · CIK 0001374175 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,866 F2 · shares: Represents matching Restricted Share Units ("MRSUs") granted to the Reporting Person in connection with the open market purchase of Common Shares of the Issuer reported on Table I (the "Purchased Shares"), pursuant to the Issuer's Matching Share Program. One-third of the MRSUs will vest on each of the first, second, and third anniversaries following the date of grant ("MRSU Grant Date"), subject to the Reporting Person's continued service (except in limited circumstances). Read SEC document |
| September 14, 2018 Filed Sep 17, 2018 18:58 UTC |
Herendeen PaulEVP and CFO
|
PurchaseCommon Stock, No Par Value | 10,000 | $22.61 | $226,100.00 |
DisclosureSEC source: 0001127602-18-027736 · form4.xml · nonDerivative · entry 1 Herendeen Paul · CIK 0001374175 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,866 F1 · price: The price in Column 4 is a weighted average price. The prices actually paid in this transaction are within the range of $22.59 to $22.63 per share. Read SEC document |
| September 14, 2018 Filed Sep 17, 2018 18:56 UTC |
PAPA JOSEPH CDirector · CHAIRMAN & CEO
|
GrantCommon Shares, No Par Value | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-027734 · form4.xml · nonDerivative · entry 2 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 687,077 F1 · shares: Represents matching Restricted Share Units ("MRSUs") granted to the Reporting Person in connection with the open market purchase of Common Shares of the Issuer reported on Table I (the "Purchased Shares"), pursuant to the Issuer's Matching Share Program. One-third of the MRSUs will vest on each of the first, second, and third anniversaries following the date of grant ("MRSU Grant Date"), subject to the Reporting Person's continued service (except in limited circumstances). Read SEC document |
| September 14, 2018 Filed Sep 17, 2018 18:56 UTC |
PAPA JOSEPH CDirector · CHAIRMAN & CEO
|
PurchaseCommon Shares, No Par Value | 30,000 | $22.32 | $669,600.00 |
DisclosureSEC source: 0001127602-18-027734 · form4.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 657,077 Read SEC document |
| September 13, 2018 Filed Sep 17, 2018 19:00 UTC |
DE SCHUTTER RICHARD UDirector
|
PurchaseCommon Stock, No Par Value | 125,000 | $23.96 | $2,995,000.00 |
DisclosureSEC source: 0001127602-18-027737 · form4.xml · nonDerivative · entry 1 DE SCHUTTER RICHARD U · CIK 0001083205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,727 F1 · price: The price in Column 4 is a weighted average price. The prices actually paid in this transaction are within the range of $23.81 to $24.07 per share. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 23:32 UTC |
Herendeen PaulEVP and CFO
|
Tax withholdingCommon Stock, No Par Value | 24,626 | $22.37 | $550,883.62 |
DisclosureSEC source: 0001127602-18-026327 · form4.xml · nonDerivative · entry 1 Herendeen Paul · CIK 0001374175 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,866 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 20:30 UTC |
APPIO THOMASPres&Co-Head Bausch&Lomb/Int'l
|
Tax withholdingCommon Stock, No Par Value | 5,501 | $21.69 | $119,316.69 |
DisclosureSEC source: 0001127602-18-026009 · form4.xml · nonDerivative · entry 1 APPIO THOMAS · CIK 0001683323 · Pres&Co-Head Bausch&Lomb/Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,585 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| August 20, 2018 Filed Sep 18, 2018 20:31 UTC Amendment |
APPIO THOMASPres&Co-Head Bausch&Lomb/Int'l
|
Tax withholdingCommon Stock, No Par Value | 6,604 | $21.69 | $143,240.76 |
DisclosureSEC source: 0001127602-18-027894 · form4a.xml · nonDerivative · entry 1 APPIO THOMAS · CIK 0001683323 · Pres&Co-Head Bausch&Lomb/Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,482 F1 · shares: This Form 4/A is being filed to correct the number of shares withheld to satisfy the tax withholding obligations due upon the vesting of Restricted Share Units. Read SEC document |
| August 09, 2018 Filed Aug 13, 2018 21:04 UTC |
ACKERMANN CHRISTINAEVP AND GENERAL COUNSEL
|
Tax withholdingCommon Stock, No Par Value | 7,779 | $23.52 | $182,962.08 |
DisclosureSEC source: 0001127602-18-025213 · form4.xml · nonDerivative · entry 1 ACKERMANN CHRISTINA · CIK 0001681871 · EVP AND GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,402 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:49 UTC |
DE SCHUTTER RICHARD UDirector
|
GrantCommon Stock, No Par Value | 1,344 | $23.24 | $31,234.56 |
DisclosureSEC source: 0001127602-18-022665 · form4.xml · nonDerivative · entry 1 DE SCHUTTER RICHARD U · CIK 0001083205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,727 F1 · shares: Represents Restricted Share Units ("RSUs") representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:41 UTC |
Paulson JohnDirector
|
GrantCommon Stock, No Par Value | 1,183 | $23.24 | $27,492.92 |
DisclosureSEC source: 0001127602-18-022655 · form4.xml · nonDerivative · entry 1 Paulson John · CIK 0001394923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,140 F1 · shares: Represents Restricted Share Units ("RSUs") representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:36 UTC |
ROBERTSON RUSSEL CDirector
|
GrantCommon Stock, No Par Value | 1,613 | $23.24 | $37,486.12 |
DisclosureSEC source: 0001127602-18-022650 · form4.xml · nonDerivative · entry 1 ROBERTSON RUSSEL C · CIK 0001677301 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,707 F1 · shares: Represents Restricted Share Units ("RSUs") representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:31 UTC |
WECHSLER AMY BDirector
|
GrantCommon Stock, No Par Value | 1,344 | $23.24 | $31,234.56 |
DisclosureSEC source: 0001127602-18-022645 · form4.xml · nonDerivative · entry 1 WECHSLER AMY B · CIK 0001677300 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,232 F1 · shares: Represents Restricted Share Units ("RSUs") representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc. Read SEC document |
| June 04, 2018 Filed Jun 6, 2018 21:15 UTC |
Eldessouky SamSVP, CHIEF ACCOUNTING OFFICER
|
Tax withholdingCommon Stock, No Par Value | 6,142 | $22.08 | $135,615.36 |
DisclosureSEC source: 0001127602-18-020184 · form4.xml · nonDerivative · entry 1 Eldessouky Sam · CIK 0001558676 · SVP, CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,117 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| May 15, 2018 Filed May 17, 2018 20:43 UTC |
DE SCHUTTER RICHARD UDirector
|
PurchaseCommon Stock, No Par Value | 15,000 | $21.83 | $327,450.00 |
DisclosureSEC source: 0001127602-18-017910 · form4.xml · nonDerivative · entry 1 DE SCHUTTER RICHARD U · CIK 0001083205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,383 F1 · price: The price in Column 4 is a weighted average price. The prices actually paid in this transaction are within the range of $21.56 to $22.05 per share. Read SEC document |
| May 15, 2018 Filed Jul 3, 2018 20:49 UTC |
DE SCHUTTER RICHARD UDirector
|
PurchaseCommon Stock, No Par Value | 10,000 | $21.80 | $218,000.00 |
DisclosureSEC source: 0001127602-18-022665 · form4.xml · nonDerivative · entry 2 DE SCHUTTER RICHARD U · CIK 0001083205 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 10,000 Read SEC document |
| May 03, 2018 Filed May 4, 2018 22:41 UTC |
Hale David RobertDirector · See Remarks
ValueAct Holdings, L.P.Director · See Remarks
ValueAct Capital Master Fund, L.P.Director · See Remarks
ValueAct Co-Invest Master Fund, L.P.Director · See Remarks
VA Partners I, LLCDirector · See Remarks
ValueAct Capital Management, L.P.Director · See Remarks
ValueAct Capital Management, LLCDirector · See Remarks
ValueAct Holdings GP, LLCDirector · See Remarks
|
GrantCommon Stock, no par value | 14,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001418812-18-000039 · primary_doc.xml · nonDerivative · entry 1 Hale David Robert · CIK 0001635643 · Director · See Remarks ValueAct Holdings, L.P. · CIK 0001418814 · Director · See Remarks ValueAct Capital Master Fund, L.P. · CIK 0001464912 · Director · See Remarks ValueAct Co-Invest Master Fund, L.P. · CIK 0001579734 · Director · See Remarks VA Partners I, LLC · CIK 0001418812 · Director · See Remarks ValueAct Capital Management, L.P. · CIK 0001351069 · Director · See Remarks ValueAct Capital Management, LLC · CIK 0001351073 · Director · See Remarks ValueAct Holdings GP, LLC · CIK 0001418813 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,897 F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of Valeant Pharmaceuticals International, Inc. ("Valeant") on the third business day following their election at the Annual Meeting of Shareholders of Valeant (the "Annual Meeting"). The RSUs have a grant date value equal to $250,000, vest immediately prior to Valeant's next Annual Meeting, and are settled in common shares, no par value, of Valeant. F2 · ownership.direct: All board compensation accrues to the benefit of the investors in ValueAct Capital Master Fund, L.P.‎, and not to any individual. Under an agreement with ValueAct Capital, D. Robert Hale is deemed to hold the restricted share units for the benefit of the limited partners of ValueAct Capital Master Fund, L.P. and indirectly for (i) VA Partners I, LLC as General Partner of ValueAct Capital Master Fund, L.P., (ii) ValueAct Capital Management, L.P. as the manager of ValueAct Capital Master Fund, L.P., (iii) ValueAct Capital Management, LLC as General Partner of ValueAct Capital Management, L.P., (iv) ValueAct Holdings, L.P. as the sole owner of the limited partnership interests of ValueAct Capital Management, L.P. and the membership interests of ValueAct Capital Management, LLC and as the majority owner of the membership interests of VA Partners I, LLC and (v) ValueAct Holdings GP, LLC as General Partner of ValueAct Holdings, L.P. F3 · ownership.direct: Each reporting person listed herein disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein, and this report shall not be deemed an admission that such person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| May 03, 2018 Filed May 4, 2018 22:02 UTC |
WECHSLER AMY BDirector
|
GrantCommon Stock, No Par Value | 14,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-016414 · form4.xml · nonDerivative · entry 1 WECHSLER AMY B · CIK 0001677300 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,292 F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of Valeant Pharmaceuticals International, Inc. ("Valeant") on the third business day following their election at the Annual Meeting of Shareholders of Valeant (the "Annual Meeting"). The RSUs have a grant date value equal to $250,000, vest immediately prior to Valeant's next Annual Meeting, and are settled in common shares, no par value, of Valeant. Read SEC document |
| May 03, 2018 Filed May 4, 2018 22:02 UTC |
Ross Thomas W. Sr.Director
|
GrantCommon Stock, No Par Value | 14,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-016413 · form4.xml · nonDerivative · entry 1 Ross Thomas W. Sr. · CIK 0001669396 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,573 F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of Valeant Pharmaceuticals International, Inc. ("Valeant") on the third business day following their election at the Annual Meeting of Shareholders of Valeant (the "Annual Meeting"). The RSUs have a grant date value equal to $250,000, vest immediately prior to Valeant's next Annual Meeting, and are settled in common shares, no par value, of Valeant. Read SEC document |
| May 03, 2018 Filed May 4, 2018 22:00 UTC |
POWER ROBERT NDirector
|
GrantCommon Stock, No Par Value | 14,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-016411 · form4.xml · nonDerivative · entry 1 POWER ROBERT N · CIK 0001187303 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,513 F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of Valeant Pharmaceuticals International, Inc. ("Valeant") on the third business day following their election at the Annual Meeting of Shareholders of Valeant (the "Annual Meeting"). The RSUs have a grant date value equal to $250,000, vest immediately prior to Valeant's next Annual Meeting, and are settled in common shares, no par value, of Valeant. Read SEC document |
| May 03, 2018 Filed May 4, 2018 22:01 UTC |
ROBERTSON RUSSEL CDirector
|
GrantCommon Stock, No Par Value | 14,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-016412 · form4.xml · nonDerivative · entry 1 ROBERTSON RUSSEL C · CIK 0001677301 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,498 F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of Valeant Pharmaceuticals International, Inc. ("Valeant") on the third business day following their election at the Annual Meeting of Shareholders of Valeant (the "Annual Meeting"). The RSUs have a grant date value equal to $250,000, vest immediately prior to Valeant's next Annual Meeting, and are settled in common shares, no par value, of Valeant. Read SEC document |
| May 03, 2018 Filed May 4, 2018 21:56 UTC |
Paulson JohnDirector
|
GrantCommon Stock, No Par Value | 14,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-016409 · form4.xml · nonDerivative · entry 1 Paulson John · CIK 0001394923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,361 F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of Valeant Pharmaceuticals International, Inc. ("Valeant") on the third business day following their election at the Annual Meeting of Shareholders of Valeant (the "Annual Meeting"). The RSUs have a grant date value equal to $250,000, vest immediately prior to Valeant's next Annual Meeting, and are settled in common shares, no par value, of Valeant. Read SEC document |
| May 03, 2018 Filed May 4, 2018 21:55 UTC |
PAPA JOSEPH CDirector · CHAIRMAN & CEO
|
Tax withholdingCommon Shares, No Par Value | 91,942 | $18.31 | $1,683,458.02 |
DisclosureSEC source: 0001127602-18-016408 · form4.xml · nonDerivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director · CHAIRMAN & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 627,077 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| May 03, 2018 Filed May 4, 2018 21:55 UTC |
KAVANAGH SARAH BDirector
|
GrantCommon Stock, No Par Value | 14,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-016407 · form4.xml · nonDerivative · entry 1 KAVANAGH SARAH B · CIK 0001681171 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,149 F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of Valeant Pharmaceuticals International, Inc. ("Valeant") on the third business day following their election at the Annual Meeting of Shareholders of Valeant (the "Annual Meeting"). The RSUs have a grant date value equal to $250,000, vest immediately prior to Valeant's next Annual Meeting, and are settled in common shares, no par value, of Valeant. Read SEC document |
| May 03, 2018 Filed May 4, 2018 21:54 UTC |
KARABELAS ARGERIS NDirector
|
GrantCommon Stock, No Par Value | 14,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-016406 · form4.xml · nonDerivative · entry 1 KARABELAS ARGERIS N · CIK 0001191229 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,417 F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of Valeant Pharmaceuticals International, Inc. ("Valeant") on the third business day following their election at the Annual Meeting of Shareholders of Valeant (the "Annual Meeting"). The RSUs have a grant date value equal to $250,000, vest immediately prior to Valeant's next Annual Meeting, and are settled in common shares, no par value, of Valeant. Read SEC document |
| May 03, 2018 Filed May 4, 2018 21:53 UTC |
DE SCHUTTER RICHARD UDirector
|
GrantCommon Stock, No Par Value | 14,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-016405 · form4.xml · nonDerivative · entry 1 DE SCHUTTER RICHARD U · CIK 0001083205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,787 F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of Valeant Pharmaceuticals International, Inc. ("Valeant") on the third business day following their election at the Annual Meeting of Shareholders of Valeant (the "Annual Meeting"). The RSUs have a grant date value equal to $250,000, vest immediately prior to Valeant's next Annual Meeting, and are settled in common shares, no par value, of Valeant. Read SEC document |
| May 03, 2018 Filed May 8, 2018 21:35 UTC Amendment |
Hale David RobertDirector · See Remarks
ValueAct Holdings, L.P.Director · See Remarks
ValueAct Capital Master Fund, L.P.Director · See Remarks
ValueAct Co-Invest Master Fund, L.P.Director · See Remarks
VA Partners I, LLCDirector · See Remarks
ValueAct Capital Management, L.P.Director · See Remarks
ValueAct Capital Management, LLCDirector · See Remarks
ValueAct Holdings GP, LLCDirector · See Remarks
|
GrantCommon Stock, no par value | 13,881 | $0.00 | $0.00 |
DisclosureSEC source: 0001418812-18-000043 · primary_doc.xml · nonDerivative · entry 1 Hale David Robert · CIK 0001635643 · Director · See Remarks ValueAct Holdings, L.P. · CIK 0001418814 · Director · See Remarks ValueAct Capital Master Fund, L.P. · CIK 0001464912 · Director · See Remarks ValueAct Co-Invest Master Fund, L.P. · CIK 0001579734 · Director · See Remarks VA Partners I, LLC · CIK 0001418812 · Director · See Remarks ValueAct Capital Management, L.P. · CIK 0001351069 · Director · See Remarks ValueAct Capital Management, LLC · CIK 0001351073 · Director · See Remarks ValueAct Holdings GP, LLC · CIK 0001418813 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,493 F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of Valeant Pharmaceuticals International, Inc. ("Valeant") on the third business day following their election at the Annual Meeting of Shareholders of Valeant (the "Annual Meeting"). The RSUs have a grant date value equal to $250,000, vest immediately prior to Valeant's next Annual Meeting, and are settled in common shares, no par value, of Valeant. F2 · shares: This Amended Form 4 is being filed to correct the number of RSUs acquired on May 3, 2018 as reported on the Form 4 filed on May 4, 2018. F3 · ownership.direct: All board compensation accrues to the benefit of the investors in ValueAct Capital Master Fund, L.P.‎, and not to any individual. Under an agreement with ValueAct Capital, D. Robert Hale is deemed to hold the restricted share units for the benefit of the limited partners of ValueAct Capital Master Fund, L.P. and indirectly for (i) VA Partners I, LLC as General Partner of ValueAct Capital Master Fund, L.P., (ii) ValueAct Capital Management, L.P. as the manager of ValueAct Capital Master Fund, L.P., (iii) ValueAct Capital Management, LLC as General Partner of ValueAct Capital Management, L.P., (iv) ValueAct Holdings, L.P. as the sole owner of the limited partnership interests of ValueAct Capital Management, L.P. and the membership interests of ValueAct Capital Management, LLC and as the majority owner of the membership interests of VA Partners I, LLC and (v) ValueAct Holdings GP, LLC as General Partner of ValueAct Holdings, L.P. F4 · ownership.direct: Each reporting person listed herein disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein, and this report shall not be deemed an admission that such person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| May 03, 2018 Filed May 8, 2018 20:43 UTC Amendment |
WECHSLER AMY BDirector
|
GrantCommon Stock, No Par Value | 13,881 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-016657 · form4a.xml · nonDerivative · entry 1 WECHSLER AMY B · CIK 0001677300 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,888 F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of Valeant Pharmaceuticals International, Inc. ("Valeant") on the third business day following their election at the Annual Meeting of Shareholders of Valeant (the "Annual Meeting"). The RSUs have a grant date value equal to $250,000, vest immediately prior to Valeant's next Annual Meeting, and are settled in common shares, no par value, of Valeant. F2 · shares: This Amended Form 4 is being filed to correct the number of RSUs acquired on May 3, 2018 as reported on the Form 4 filed on May 4, 2018. Read SEC document |
| May 03, 2018 Filed May 8, 2018 20:42 UTC Amendment |
Ross Thomas W. Sr.Director
|
GrantCommon Stock, No Par Value | 13,881 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-016656 · form4a.xml · nonDerivative · entry 1 Ross Thomas W. Sr. · CIK 0001669396 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,169 F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of Valeant Pharmaceuticals International, Inc. ("Valeant") on the third business day following their election at the Annual Meeting of Shareholders of Valeant (the "Annual Meeting"). The RSUs have a grant date value equal to $250,000, vest immediately prior to Valeant's next Annual Meeting, and are settled in common shares, no par value, of Valeant. F2 · shares: This Amended Form 4 is being filed to correct the number of RSUs acquired on May 3, 2018 as reported on the Form 4 filed on May 4, 2018. Read SEC document |
| May 03, 2018 Filed May 8, 2018 20:39 UTC Amendment |
ROBERTSON RUSSEL CDirector
|
GrantCommon Stock, No Par Value | 13,881 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-016655 · form4a.xml · nonDerivative · entry 1 ROBERTSON RUSSEL C · CIK 0001677301 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,094 F1 · shares: Represents the award of restricted share units ("RSUs") granted to non-employee directors of Valeant Pharmaceuticals International, Inc. ("Valeant") on the third business day following their election at the Annual Meeting of Shareholders of Valeant (the "Annual Meeting"). The RSUs have a grant date value equal to $250,000, vest immediately prior to Valeant's next Annual Meeting, and are settled in common shares, no par value, of Valeant. F2 · shares: This Amended Form 4 is being filed to correct the number of RSUs acquired on May 3, 2018 as reported on the Form 4 filed on May 4, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.